Asia · Regional markets · Vietnam Investment Review

BioVersys initiates Phase 2b trial for anti infective drug BV100

Published by Vietnam Investment Review · Vietnam 8 h ago

Biotechnology company BioVersys enrolled the first patient in its Phase 2b trial evaluating anti-infective drug candidate BV100 for treating drug-resistant bacterial pneumonia.

Read the full article on Vietnam Investment Review Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading

CNBC-TV18

Q2 Results Live Updates: IGL profit down 89%, Juniper Green Energy PAT down 7.6%

The Straits Times Business

Binance co-founder Zhao tells Musk ‘bad time to troll’ after record hack

Mint

Vijay Kedia's portfolio stock under ₹150: This textile stock adds ₹3.7 crore to his wealth since IPO; Do you own?

Business Standard

Bengaluru matches Tokyo with 11.5% office rent growth in Q3: Knight Frank

The Business Times

Nuclear potential, data centre boom may be addressed in new Asean energy masterplan

Tech in Asia